Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

  1. Pabst, T.
  2. Papayannidis, C.
  3. Demirkan, F.
  4. Doronin, V.
  5. Fogliatto, L.M.
  6. Guttke, C.
  7. Gyan, E.
  8. Hamad, N.
  9. Herrera, P.
  10. Hultberg, A.
  11. Jacobs, J.
  12. Johnson, A.J.
  13. Langlois, A.
  14. Ma, X.
  15. Martinelli, G.
  16. Arnan, M.
  17. Müller, R.
  18. Nottage, K.
  19. Ofran, Y.
  20. Özcan, M.
  21. Samoilova, O.
  22. Tolbert, J.A.
  23. Trudel, G.C.
  24. Xiu, L.
  25. Vey, N.
  26. Wei, A.H.
  27. Show all authors +
Journal:
The Lancet Haematology

ISSN: 2352-3026

Year of publication: 2023

Volume: 10

Issue: 11

Pages: e902-e912

Type: Article

DOI: 10.1016/S2352-3026(23)00207-7 GOOGLE SCHOLAR
Data source: Scopus